Ronald de Wit

Search results

• 2022

  Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

  Balar, A. V., Kamat, A. M., Kulkarni, G. S., Uchio, E. M., Boormans, J. L., Roumiguié, M., Krieger, L. E. M., Singer, E. A., Bajorin, D. F., Grivas, P., Seo, H. K., Nishiyama, H., Konety, B. R., Li, H., Nam, K., Kapadia, E., Frenkl, T. & De Wit, R., 1 Jul 2022, In: Journal of Urology. 208, 1, p. 212 1 p.

  Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review